相关实验视频
Updated: Feb 28, 2026

08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
69.1K
在炎症性肠病中的血清生物标志物的推算方法
Miad Boodaghidizaji1, Dermot P B McGovern1, Dalin Li2
1F. Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Scientific reports
|February 26, 2026
概括
在炎症性肠病 (IBD) 研究中缺少血清学数据可能会导致结果偏差. 这项研究比较了多种归算方法,发现代式输入器有效用于低缺失率和自动编码器用于更高水平,优化IBD数据分析.
科学领域:
- 生物医学信息学 生物医学信息学
- 统计建模 统计建模
- 炎症性肠道疾病研究研究
背景情况:
- 血清生物标志物对于炎症性肠病 (IBD) 的诊断和亚型化至关重要.
- 血清学数据集中缺少的数据可能会损害统计和机器学习分析,导致有偏见的预测.
研究的目的:
- 为了全面比较IBD中的血清学数据的各种多重归算模型.
- 在不同的缺失数据机制 (MCAR, MAR, MNAR) 和不同缺失百分比下评估归算性能.
主要方法:
- 使用了三种不同的归算技术:通过链式方程进行多重归算 (MICE),代归算器 (II) 和自动编码器 (AE).
- 在三个真实世界IBD队列和2400个模拟场景中评估了归算模型.
- 基于直接准确性,推断信号保存和预测实用性的评估性能.
主要成果:
- 没有单一的归算方法在所有场景中证明了普遍的优越性.
- 代归算方法 (II-BR,KNN,RF) 在低至中度失踪水平上通常表现更好.
- 基于自动编码器的方法 (AE,VAE) 显示出更强大的稳定性,缺失数据的百分比增加.
结论:
- 对IBD血清学数据的归算方法的选择应以缺失程度为指导.
- 代式输入器适用于不太完整的数据集,而自动编码器为高度不完整的数据提供了更强大的解决方案.
- 队列内部分析对于防止信息泄露和确保可靠的归算结果至关重要.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
972
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
972
Inflammatory Bowel Disease IV: Pharmacological Management
860
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
860
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
658
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
658
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604

